Analysis of risk factors for esophagogastric variceal bleeding in liver cirrhosis
LIU Limin1,2 ZHU Bin1,2
1.Department of Infectious Diseases, the First Affiliated Hospital of Xinxiang Medical College, He′nan Province, Xinxiang 453000, China;
2.the First Clinical College, Xinxiang Medical College, He′nan Province, Xinxiang, 453000, China
Abstract：Objective To investigate the risk factors of esophagogastric variceal bleeding (EVB) in patients with liver cirrhosis. Methods A total of 185 patients with liver cirrhosis complicated with esophagogastric varices treated in the First Affiliated Hospital of Xinxiang Medical College from July 2017 to July 2019 were retrospectively collected. They were divided the into bleeding group and the non-bleeding group according to whether they were complicated with EVB. There were 125 cases in the non-bleeding group and 60 cases in the bleeding group. The general data, laboratory indexes, Child-Pugh classification of liver function, gastroscopy results, ultrasound or imaging examination results of the two groups were analyzed by univariate analysis, and the indexes with statistical significance differences after univariate analysis were analyzed by binary logistic regression analysis. Results The white blood cell count, total bilirubin, the activated partial thromboplastin time and serum creatinine levels were no significant differences between the two groups (P ＞ 0.05). The serum albumin and fibrinogen and platelet count in the bleeding group were lower than those in the non-bleeding group, and the differences were statistically significant (all P ＜ 0.05). The prothrombin time and thrombin time in the bleeding group were longer than those in the non-bleeding group, and the differences were statistically significant (all P ＜ 0.05). The diameter of portal vein and the thickness of spleen in the bleeding group were wider than those in the non-bleeding group, and the differences were statistically significant (all P ＜ 0.05). Compared with the non-bleeding group, there were statistically significant differences in red sign, severe esophageal varices, gastric varices, portal vein thrombosis, ascites, and Child-Pugh classification of liver function in the bleeding group (P ＜ 0.05). Binary logistic regression results showed that serum albumin was the protective factor of EVB (OR = 0.874, 95%CI: 0.788-0.968, P = 0.01), the severe esophageal varices (OR = 4.389, 95%CI: 1.084-17.774, P = 0.038) and red sign (OR = 4.106, 95%CI: 1.392-12.113, P = 0.011) were the independent risk factors of EVB. Conclusion The red sign and severe esophageal varices are the independent risk factors of EVB complicated with liver cirrhosis, and serum albumin is the protective factor.
[1] 陈平，吴云林.重视门静脉高压的基础与临床研究[J].中华消化病与影像杂志，2018，8（6）：241-244.
[2] Seo YS. Prevention and management of gastroesophageal varices [J]. Clin Mol Hepatol，2018，24（1）：20-42.
[3] Takehara T，Sakamori R. Remaining challenges for the noninvasive diagnosis of esophageal varices in liver cirrhosis [J]. Esophagus，2020，17（1）：19-24.
[4] Toubia N，Sanyal AJ. Portal hypertension and variceal hemorrhage [J]. Me Clin North Am，2008，92（3）：551-574.
[5] Cat TB，Liu-DeRyke X. Medical management of variceal hemorrhage [J]. Crit Care Nurs Clin North Am，2010，22（3）：381-393.
[6] 穆雪纯，王宇，马红.肝硬化门静脉高压的无创评估[J].临床肝胆病杂志，2019，35（12）：2796-2799.
[7] 中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志，2016，32（2）：203-219.
[8] 中华医学会肝病学分会.肝硬化诊治指南[J].实用肝脏病杂志，2019，22（6）：770-786.
[9] Ibrahim M，Mostafa I，Devière J. New Developments in Managing Variceal Bleeding [J]. Gastroenterology，2018，154（7）：1964-1969.
[10] Bosch J，Abraldes JG，Berzigotti A，et al. The clinical use of HVPG measurements in chronic liver disease [J]. Nat Rev Gastroenterol Hepatol，2009，6（10）：573-582.
[11] 左晨艳，张瑜，刘澄，等.门静脉高压血清学评估的研究进展[J].胃肠病学，2019，24（10）：631-634.
[12] Kovacs TOG，Jensen DM. Varices：Esophageal，Gastric，and Rectal [J]. Clin Liver Dis，2019，23（4）：625-642.
[13] European Association for the Study of the Liver，Electronic address: easloffice@easloffice.eu，European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [J]. J Hepatol，2018，69（2）：406-460.
[14] Bosch J，Groszmann RJ，Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension：How changes in paradigm are leading to successful new treatments [J]. J Hepatol，2015，62（1 Suppl）：S121-S130.
[15] 林秋满，王桂良，邱萍，等.内镜处理联合不同使用时程奥曲肽治疗食管胃底静脉曲张破裂出血的效果-成本分析[J].中国现代医生，2019，57（18）：15-19.
[16] 苏有盛，吴封.内镜下食管静脉曲张套扎术后早期再出血的危险因素分析[J].中国医学工程，2018，26（1）：27-29.
[17] 和庆章，王桂良，邱萍，等.内镜处理联合国产生长抑素或进口生长抑素治疗食管胃底静脉曲张破裂出血的效果分析[J].中国现代医生，2019，57（26）：40-43，47.
[18] 王娟，郑鸽之.肝硬化食管静脉曲张破裂出血相关因素分析[J].中国肝脏病杂志：电子版，2019，11（1）：42-46.
[19] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].实用肝脏病杂志，2018，21（1）：21-31.
[20] 翁慧斌，万秀萍，林海，等.肝硬化合并食管胃底静脉曲张患者发生上消化道出血的危险因素分析[J].现代实用医学，2018，30（11）：1467-1468.
[21] 张小军，郭艳，朱祈锋.食管胃底静脉曲张破裂出血在肝硬化患者中的相关因素分析[J].山西医药杂志，2016， 45（16）：1865-1867.
[22] Caraceni P，Riggio O，Angeli P，et al. Long-term albumin administration in decompensated cirrhosis（ANSWER）：an open-label randomised trial [J]. Lancet，2018，391（10138）：2417-2429.
2020, Vol. 17 
京公网安备 11010502046598号